TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06916806: An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus

Sponsor: AstraZeneca · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT06916806 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06916806 Rescue Dossier →